Clinical trial NCT04725331: A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Official title: A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Metastatic Cancer
Soft Tissue Sarcoma
Merkel Cell Carcinoma
Melanoma
Triple Negative Breast Cancer
Non Small Cell Lung Cancer
Keywords: Superficial tumors
Metastatic cancer
Intratumoral
Safety
Oncolytic virus
Vaccinia virus
Solid tumors
Melanoma
Merkel
Sarcoma
TNBC
NSCLC
Pembrolizumab
BT-001
TG6030
Phase 1
Lead sponsor: Transgene
Sponsor class: INDUSTRY
Collaborators: name: BioInvent International AB
name: Merck Sharp & Dohme LLC
First posted: 2021-01-26
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.

Detailed description: This study will include 3 parts:

* Phase I, Part A: Repeated intra-tumoral (IT) administrations of BT-001 as a single agent, in patients with metastatic/advanced solid tumors; dose-escalation will be employed.
* Phase I, Part B: Repeated IT administrations of BT-001 in combination with intravenous (IV) infusions of pembrolizumab in patients with metastatic/advanced soft tissue sarcoma (STS), Merkel cell carcinoma (MCC), melanoma, triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC)..
* Phase IIa: Repeated IT administrations of BT-001 in combination with IV infusions of pembrolizumab in several cohorts of patients with defined metastatic or advanced solid tumor conditions.

Eligibility criteria: Inclusion Criteria:

* Have at least 1 injectable measurable cutaneous, subcutaneous or nodal lesion (direct injection or through the use of ultrasound guidance) not exceeding 50mm in longest diameter and whenever possible 1 distant non-injected measurable lesion.
* Provision of a fresh tumor sample of the lesion that will be injected first and, whenever possible, from another lesion that is planned to be injected, at baseline and be willing to supply new tumor samples from a biopsy during treatment.
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
* Have adequate hematological, hepatic and renal functions.
* Have histologically confirmed, advanced/metastatic sarcoma (soft tissue and bone), Merkel cell carcinoma, melanoma, triple negative breast cancer or non-small cell lung cancer, with cutaneous or, palpable subcutaneous lesions or easily injectable lymph nodes.
* Have failed and/or are intolerant to standard therapeutic options.

Exclusion Criteria:

* Have had major surgery within 4 weeks of first study drug administration.
* Have received prior treatment with a vaccinia oncolytic virus.
* Have received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to the start of treatment.
* Have received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 28 days prior the first dose of study drugs
* Have a known additional malignancy that is progressing or has required active treatment within the past 3 years.
* Have an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
* Have a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease
* Have an active infection requiring systemic therapy
* Have a known history of HIV infection
* Is taking an anticoagulant medication that cannot be interrupted prior to IT injections
* Have had an allogenic tissue/solid organ transplant or allogenic stem cell or bone marrow transplantation
* History of severe exfoliative skin conditions (e.g., eczema or atopic dermatitis) requiring systemic therapy for more than 4 weeks within 2 years prior to BT-001 initiation.
* Have received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher immune-related Adverse Event (irAE).
* Have known active CNS metastases and/or carcinomatous meningitis.
* Have a known history of Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection.n.
* Woman of childbearing potential who has a positive serum pregnancy test (within 72 hours) prior to the start of treatment.
* Have received or receiving any live or live-attenuated vaccine within 30 days prior to the first dose of study intervention..
* History of myocarditis or congestive heart failure, unstable angina, uncontrolled infection, or myocardial infarction 6 months prior to clinical trial entry.
* Interstitial lung disease that is symptomatic and may interfere with the detection or management of suspected drug-related pulmonary toxicity
* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
* Have severe hypersensitivity to the active substance or, to any of the excipients of (≥Grade 3) to pembrolizumab. and/or any of its excipients

Primary outcomes:
measure: Phase I: Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0)
timeFrame: Up to 5 years
measure: Phase I, Part A: Recommended dose for Part B (RDPB) definition
timeFrame: Week 10-12
measure: Phase IIa (except Soft Tissue Sarcoma cohort): Immune Overall Response Rate (iORR) by iRECIST
timeFrame: Up to 2 years
measure: Phase IIa (Soft Tissue Sarcoma cohort): Immune Disease Control Rate (iDCR) at 6 months by iRECIST
timeFrame: Up to 6 months
Secondary outcomes:
measure: Phase IIa: Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0)
timeFrame: Up to 5 years
measure: Disease Control Rate (DCR) and immune DCR by RECIST version 1.1 and iRECIST
timeFrame: 4 months or 6 months
measure: Progression Free Survival (PFS) and immune PFS duration by RECIST version 1.1 and iRECIST
timeFrame: Up to 2 years
measure: Duration of overall Response (DoR) and immune DOR by RECIST version 1.1 and iRECIST
timeFrame: Up to 2 years
measure: Overall Survival (OS) duration
timeFrame: Up to 2 years
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Clinique Universitaire Saint-Luc
city: Bordeaux
country: France
facility: Institut Bergonié
city: Lyon
country: France
facility: Centre Léon Bérard
city: Paris
country: France
facility: Hôpital Saint-Louis AP-HP
city: Villejuif
country: France
facility: Institut Gustave Roussy
Study officials:
References: